50 results about "Transient paresthesia" patented technology

An implantable pulse generator includes a current steering capability that allows a clinician or patient to quickly determine a desired electrode stimulation pattern, including which electrodes of a group of electrodes within an electrode array should receive a stimulation current, including the amplitude, width and pulse repetition rate of such current. Movement of the selected group of electrodes is facilitated through the use of remotely generated directional signals, generated by a pointing device, such as a joystick. As movement of the selected group of electrodes occurs, current redistribution amongst the various electrode contacts takes place. The redistribution of stimulus amplitudes utilizes re-normalization of amplitudes so that the perceptual level remains fairly constant. This prevents the resulting paresthesia from falling below the perceptual threshold or above the comfort threshold.

Devices, systems and methods are provided for treating pain while minimizing or eliminating possible complications and undesired side effects, particularly the sensation of paresthesia. This is achieved by stimulating in proximity to a dorsal root ganglion with stimulation energy in a manner that will affect pain sensations without generating substantial sensations of paresthesia. In some embodiments, such neurostimulation takes advantage of anatomical features and functions particular to the dorsal root ganglion.

An apparatus for treating pain by electrical stimulation is disclosed. A lead is placed subcutaneously in the region of pain. The subcutaneous tissue is electrically stimulated to cause paresthesia. The method encompasses subcutaneous placement of an electrical lead near the region of pain and subsequent electrical stimulation of the tissue to cause paresthesia. In particular, an apparatus for treating intractable occipital neuralgia using percutaneous electrostimulation techniques is disclosed.

An implantable pulse generator includes a current steering capability that allows a clinician or patient to quickly determine a desired electrode stimulation pattern, including which electrodes of a group of electrodes within an electrode array should receive a stimulation current, including the amplitude, width and pulse repetition rate of such current. Movement of the selected group of electrodes is facilitated through the use of remotely generated directional signals, generated by a pointing device, such as a joystick. As movement of the selected group of electrodes occurs, current redistribution amongst the various electrode contacts takes place. The redistribution of stimulus amplitudes utilizes re-normalization of amplitudes so that the perceptual level remains fairly constant. This prevents the resulting paresthesia from falling below the perceptual threshold or above the comfort threshold.

Methods for selecting stimulation parameter sets guide a clinician towards an effective set(s) of stimulation parameters. The clinician first evaluates the effectiveness of a small number of trial stimulation parameters sets from a Measurement Table comprising for example, four stimulation parameter sets, measuring the perception threshold and maximum threshold levels. The maximum comfortable step size and desired field shift resolution are determined, and are used along with the measured threshold levels to determine an appropriate step size to use in the current steering process. In order to maintain paresthesia at a relatively constant level during the steering process, a Superposition Equalization (SEQ) algorithm is used to compensate for the physical characteristics of the lead array, i.e., electrode separation and size. A multiplier is determined and a modifying function is used to apply this multiplier to the electrode energy output during transition to maintain a relatively constant current density.

A stimulation system includes a stimulation source, an implantable stimulation lead, an implantable sensing device, and a controller. The stimulation source generates and transmits stimulation pulses to stimulation electrodes on the stimulation lead. The stimulation electrodes deliver the stimulation pulses to target nerve tissue in a nerve pathway to cause paresthesia in a portion of the person's body. Each stimulation pulse induces an action potential in a number of nerve fibers in the nerve pathway. The sensing device includes sensing electrodes positioned proximate the nerve pathway that detect compound action potentials of nerve fibers stimulated by the stimulation pulses. The controller modifies the stimulation pulses generated by the stimulation source and delivered to the target nerve tissue by the stimulation electrodes based on the detected compound action potentials to maintain a substantially constant level of paresthesia in the portion of the person's body.

A method of providing therapy to a patient. The method comprises conveying pulsed electrical current at a defined pulse width and a defined pulse rate into spinal cord tissue. The defined pulse width is equal to or less than 200 μs, and the defined pulse rate is less than 1500 Hz, such that neural elements in the dorsal horn are modulated and / or the patient does not perceive paresthesia during the conveyance of the pulsed electrical current into the spinal cord tissue.

A method comprises conveying a pulsed waveform between an electrode and a stimulation site of a spinal cord, thereby evoking the antidromic propagation of action potentials along a first sensory neural fiber creating a therapeutic effect in the tissue region, evoking the orthodromic propagation of action potentials along the first sensory neural fiber potentially creating paresthesia corresponding to the tissue region, and evoking the antidromic propagation of action potentials along a second sensory neural fiber potentially creating a side-effect in another tissue region. The method further comprises conveying electrical energy between an electrode and a blocking site rostral to the stimulation site, thereby blocking the action potentials propagated along the first sensory neural fiber and reducing the paresthesia, and conveying electrical energy between an electrode and a blocking site caudal to the stimulation site, thereby blocking the action potentials propagated along the second sensory neural fiber and reducing the side-effect.

A method for treating female sexual dysfunction by subcutaneous electrical stimulation of a peripheral nerve innervating at least a portion of the vulva is disclosed. A lead is placed subcutaneously over a peripheral nerve that innervates at least a portion of the vulva and clitoris. The peripheral nerve is electrically stimulated to cause paresthesia. The method encompasses subcutaneous placement of an electrical lead near any peripheral nerve innervating at least a portion of the vulva and subsequent electrical stimulation of the nerve to cause paresthesia. Further, a method for treating intractable pain of the vulva using percutaneous and subcutaneous peripheral nerve electrostimulation techniques is disclosed.

A neuromodulation system and method of providing therapy to a patient. Electrical energy is delivered to the patient in accordance with a modulation parameter, thereby providing therapy to the patient, and the modulation parameter of the delivered electrical energy is varied over a period of time, such that the delivered electrical energy is continually maintained at a sub-threshold level throughout the period of time. The sub-threshold level may be referred to as a patient-perception threshold, which may be referred to as a boundary below which a patient does not sense delivery of the electrical energy. For example, in a spinal cord modulation system, the patient-perception threshold may be a boundary below which a patient does not experience paresthesia.

A computer implemented method and system is provided for managing neural stimulation therapy. The method comprises under control of one or more processors configured with program instructions. The method delivers a series of candidate stimulation waveforms having varied stimulation intensities to at least one electrode located proximate to nervous tissue of interest. A parameter defines the candidate stimulation waveforms is changed to vary the stimulation intensity. The method identifies a first candidate stimulation waveform that induces a paresthesia-abatement effect, while continuing to induce a select analgesic effect. The method further identifies a second candidate stimulation waveform that does not induce the select analgesic effect. The method sets a stimulation therapy based on the first and second candidate stimulation waveforms.

This invention provides a new technology for management of back pain by stimulating the spinal cord in a manner that renders it refractory to transmission of deleterious or undesirable sensory input. The electrical stimulus comprises high frequency pulses in a regular or complex pattern or that are stochastically produced under microprocessor control. The stimulus is applied directly to the surface of the spinal cord from within the spinal canal, which provides important benefits over previous technology. The stimulus alleviates symptoms and signs of back pain, while minimizing the risk of side effects such as paresthesia, and potentially minimizing the effects on motor neuron transmission and proprioception.

A method of operating an implantable neuromodulator coupled to an electrode array implanted adjacent tissue of a patient includes conveying electrical modulation energy to the tissue per a series of modulation parameter sets, thereby displacing the locus of the resulting electrical field laterally relative to the tissue, associating a plurality of different loci with the modulation parameter sets, causing the patient to perceive paresthesia, identifying a modulation parameter set as creating an electrical field having a locus disposed on a physiological midline of the patient based on the perceived paresthesia, deriving another modulation parameter set from the identified modulation parameter set, conveying electrical modulation energy to the patient per the other modulation parameter set, thereby creating an electrical field having a locus relative to the tissue that is the same as the locus of the electrical field associated with the identified modulation parameter set, without causing paresthesia.

It has been discovered that pain felt in a given region of the body can be treated by stimulating a peripheral nerve at a therapeutically effective distance from the region where pain is felt to generate a comfortable sensation (i.e., paresthesia) overlapping the regions of pain. A method has been developed to reduce pain in a painful region following limb joint replacement by stimulating a peripheral nerve innervating the painful region with an electrode inserted into tissue and spaced from the peripheral nerve. This method may be used to help alleviate postoperative pain in patients following total knee arthroplasty surgery or other limb joint replacement surgeries.

A method for determining an effectual placement of an electrode array during a surgical procedure to implant the lead is provided. This method involves placing a lead having electrodes in a first location in a patient then (1) activating electrical stimulation to produce paresthesia, (2) “electronically trolling” the length of the electrode array and (3) determining whether the paresthesia is in an effective location. If the paresthesia is not in an effective location to match the location of the pain, the lead is moved to a different location steps (1) through (3) are repeated. The process of electronically trolling involves moving the electrical stimulation along the electrode array so that all regions of the electrode array provide stimulation. This method reduces or eliminates the need to move the lead during the implant procedure and thus simplifies the implant procedure compared to the currently used physical trolling method, reducing the risks to the patient. Additionally, this method saves time and improves outcomes by allowing multiple electrode combinations to be tested in a relatively short amount of time.

The present invention relates to a preventive and / or therapeutic agent for hyperkalemia, and a potassium excretion promoter containing EP4 agonist. Since EP4 agonist promotes potassium excretion, it is useful as a preventive and / or therapeutic agent for hyperkalemia. In addition, if selective EP4 agonist uses, it is a preventive and / or therapeutic agent for hyperkalemia without side effects. Further, if EP4 agonist is used, it is useful as improving agent for various symptoms (e.g. paresthesia, error of perception, weakness, myoparalysis, nausea, vomit, abdominal pain, diarrhea, arrhythmia, atrioventricular block, ventricular fibrillation, atrial fibrillation, cardiac arrest, asphyxia and / or dyspnoea etc.).

A computer-assisted stimulation programming of an implantable medical device is performed. A perception threshold is determined for a plurality of contacts on a lead configured to be implanted inside a patient. The perception threshold is determined by automatically performing a first sweep of the plurality of contacts and automatically performing a second sweep of a stimulation parameter. A paresthesia coverage provided by the plurality of contacts is determined by automatically performing a third sweep of the plurality of contacts and automatically performing a fourth sweep of the stimulation parameter. The fourth sweep is performed based on the determined perception thresholds. The first sweep, the second sweep, the third sweep, and the fourth sweep are performed without needing a manual input from a human user. A subset of the contacts corresponding to the paresthesia coverage is selected. In response to user input, stimulation programming is performed using the subset of contacts.

A method of operating an implantable neuromodulator includes calculating an index for each of a plurality of modulation parameter sets, wherein each modulation parameter set includes a respective plurality of modulation parameters from which the respective index is calculated, serially conveying electrical modulation energy to a patient in accordance with each of the plurality of modulation parameter sets, causing the patient to perceive paresthesia in response to the conveyance of the electrical modulation energy to the tissue in accordance with one of the plurality of modulation parameter sets, identifying the calculated index for that one modulation parameter set as a perception threshold index based on the perceived paresthesia, and storing the identified perception threshold index. The method may also include determining a new modulation parameter set based on the identified perception threshold index, and conveying electrical modulation energy to the tissue in accordance with the new modulation parameter set.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

The present disclosure involves a method of data-reducing and storing a sensation map. A sensation map associated with a patient is provided. The sensation map includes a graphical depiction of a sensation experienced by the patient. The sensation may be pain or paresthesia experienced by the patient in response to an electrical stimulation therapy. A data file is generated. The data file has a data size less than a data size of the sensation map. The data file contains digital information allowing a reconstruction of the sensation map. Electronic communication is then established with an implanted medical device located inside the patient's body. Thereafter, the data file is sent to the implanted medical device for storage. The stored data files are retrievable by another clinician programmer later to reconstruct the sensation map.